Phase II trial of imaging agent [64Cu]SARTATE enrolls patients with known or suspected NETs Feb. 19, 2021
Rucaparib demonstrates promising activity in BAP1-negative or BRCA1-negative mesothelioma Feb. 19, 2021
MK-6482 show promising activity in ccRCC both as monotherapy and in combination with cabozantinib Feb. 19, 2021
U.K. clearance for first-in-human study of Avacta's FAP-activated doxorubicin prodrug AVA-6000 Feb. 18, 2021
RSS